Acorda Therapeutics
15 Skyline Drive
Hawthorne
New York
10532
United States
Tel: 914-347-4300
Fax: 914-347-4560
Website: http://www.acorda.com/
Email: acorda@acorda.com
About Acorda Therapeutics
Acorda Therapeutics is a privately held biotechnology company developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS.Fampridine-SR acts to combat the effects of demyelination in the spinal cord. Myelin is the insulating sheath around nerve processes; when it is damaged due to trauma or disease, electrical impulses from the brain cannot be conducted past the demyelinated area. Fampridine-SR chemically blocks the exposed voltage-gated potassium channels, allowing the impulse from the brain to be conducted more normally past the area of damage. Fampridine is being studied in Phase 3 clinical trials to evaluate its efficacy in reducing spasticity in people with chronic spinal cord injury. Secondary endpoints in the study include evaluating its effect on bladder, bowel, and sexual function. The Company is also conducting a 152 patient, late Phase 2 clinical study in MS to evaluate Fampridine-SR's efficacy in walking speed and muscle strength.
Acorda's technology platform also includes two remyelinating agents in preclinical development for MS. The first is M1, a class of human monoclonal antibodies that have been shown to remyelinate the central nervous system in animal models, and the second is GGF2, a product of the neuregulin 1 gene. Preclinical studies have shown that GGF2 can stimulate the cell growth necessary to protect and regenerate damaged myelin. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain.
In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.
Key Management:
Ron Cohen, M.D., President and CEO Andrew R. Blight, Ph.D., Executive Vice President, Research & Development Mary Fisher, Vice President, Marketing and Strategic Planning Elliott A. Gruskin, Ph.D., Vice President, Research & Development Mitchell Katz, Ph.D., Vice President, Clinical Programs David Lawrence, Vice President, Finance Mark R. E. Pinney, C.F.A., Chief Financial Officer and Director Harold Safferstein, Ph.D., J.D., Vice President, Business Development
Last Updated: 05-09-03
553 articles with Acorda Therapeutics
-
Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America
5/11/2022
Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Biopas Laboratories today announced that they have entered into distribution and supply agreements to commercialize INBRIJA® in Latin America.
-
Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022
5/4/2022
Acorda Therapeutics, Inc. will host a webcast/conference call in conjunction with its first quarter 2022 update and financial results on Wednesday, May 11 at 4:30 p.m. ET.
-
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
3/9/2022
Acorda Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2021.
-
Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
2/24/2022
Acorda Therapeutics, Inc. will host a webcast/conference call in conjunction with its fourth quarter and year end 2021 update and financial results on Wednesday, March 9 at 4:30 p.m. ET.
-
Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
1/4/2022
Acorda Therapeutics, Inc. announced that Ron Cohen, MD, President and CEO, will present at the H.C. Wainwright BIOCONNECT Virtual Conference, taking place from January 10 – 13, 2022.
-
Companies large and small have increased the prices of their drugs so far this week. The drug price increases when the market is seeing high inflation.
-
John Varian Joins Acorda Therapeutics Board of Directors
1/3/2022
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that John Varian has joined its board of directors, effective January 1, 2022.
-
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
-
Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team
11/9/2021
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the third quarter 2021 and changes to its leadership team.
-
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany
11/9/2021
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals GmbH (ESTEVE) to commercialize INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in Germany.
-
Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021
11/2/2021
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a Webcast in conjunction with its third quarter 2021 update and financial results on Tuesday, November 9, at 4:30 p.m. ET.
-
Acorda Therapeutics is reducing its staff count by 15% effective immediately as it struggles to bring operating costs down and hit expected revenue.
-
Acorda Therapeutics Announces Corporate Restructuring, Management Changes
9/9/2021
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced a corporate restructuring to reduce costs and more closely align operating expenses with expected revenue.
-
Acorda Therapeutics Reports Second Quarter 2021 Financial Results
8/5/2021
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the second quarter 2021.
-
Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021
7/30/2021
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its second quarter 2021 update and financial results on Thursday, August 5 at 4:30 p.m. ET.
-
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain
7/22/2021
Acorda Therapeutics, Inc. announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A to commercialize INBRIJA® 33 mg in Spain.
-
Acorda Therapeutics Announces Repayment of Convertible Senior Notes
6/16/2021
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that on June 15, 2021, it repaid in full its 1.75% Convertible Senior Notes due 2021.
-
Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021
4/29/2021
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its first quarter 2021 update and financial results on Thursday, May 6 at 4:30 p.m. ET.
-
Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela℠”
4/12/2021
Culinary icon Zarela Martinez and Acorda Therapeutics (NASDAQ: ACOR) have partnered to launch “A Taste for Life with Zarela” to celebrate Parkinson’s Awareness Month. The video series showcases Zarela’s inspirational “building blocks” for living well with Parkinson’s disease (PD) and for healthy and delicious eating.
-
Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference
3/8/2021
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the March 9th & 10th H.C. Wainwright Global Life Sciences Virtual Conference.